PulseAugur
EN
LIVE 21:45:53

US faces breast biopsy needle shortage until March 2027 after Hologic recall

By PulseAugur Editorial · [1 sources] ·

A shortage of breast biopsy needles is impacting cancer detection in the United States, with the Food and Drug Administration predicting the scarcity will last until March 2027. This shortage stems from a recall initiated by Hologic Inc. in January due to reports of needle components dislodging and remaining in patients. Hologic, acquired by Blackstone Inc. and TPG Inc., is working to resolve the issue and aims to have the needles back on the market by the end of 2026, while also addressing past safety concerns with other products like the BioZorb tissue marker. AI

RANK_REASON Product recall causing a shortage of a medical device.

Read on Fortune →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

US faces breast biopsy needle shortage until March 2027 after Hologic recall

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Product recall causing a shortage of a medical device.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, safety, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
101 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Fortune TIER_1 English(EN) · Annika Inampudi, Anna Edney, Bloomberg ·

    Needles used to detect breast cancer in shortage from recall

    Hologic aims to bring the needles back on the market by the end of 2026.

RELATED ENTITIES

RELATED TOPICS